The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.

Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...

Dosing has begun in a long-term extension study testing Satellos Bioscience’s experimental oral therapy SAT-3247 in men with ...

Sarepta Therapeutics' shares plunged nearly 40% in premarket trading on Tuesday as failure of two of its approved drugs for a ...

Because researchers have made such striking progress in developing drugs to treat neuromuscular diseases, Scott Delp, Ph.D., ...

Shares in Sarepta Therapeutics lost nearly 40% of their value after the company said a trial designed to confirm the efficacy ...

Sarepta nevertheless plans to push for full FDA approval of Vyondys 53 and Amondys 45 based on what it said are “encouraging ...

Sarepta Therapeutics delivered a disastrous third-quarter earnings performance. A long-delayed confirmatory clinical trial of ...

Shares plunge 36% after nine-year DMD drug trial misses endpoint. Q3 revenue beats but clinical failure dominates sentiment.

Two of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) candidates have failed to reach their primary endpoint in a Phase III confirmatory trial. In the ESSENCE study, AMONDYS 45 (casimersen) ...

A long-running confirmatory trial of two of Sarepta Therapeutics’ Duchenne muscular dystrophy drugs has missed its main goal.